Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 1/2 1Phase 1 1

Status

Active not recruiting 4Recruiting 2

Sponsor Class

OTHER 3INDUSTRY 3

Study Type

Interventional 6

Sponsor

Cancer Type

Genitourinary 6

Conditions

Prostatic Neoplasms 1617Carcinoma, Renal Cell 497Urinary Bladder Neoplasms 459Carcinoma, Transitional Cell 233Breast Neoplasms 225Kidney Neoplasms 214Neoplasms 190Carcinoma, Non-Small-Cell Lung 173Colorectal Neoplasms 168Ovarian Neoplasms 161Melanoma 161Neoplasm Metastasis 142Lung Neoplasms 127Non-Muscle Invasive Bladder Neoplasms 104Pancreatic Neoplasms 101Stomach Neoplasms 99Uterine Cervical Neoplasms 91Squamous Cell Carcinoma of Head and Neck 86Endometrial Neoplasms 82Carcinoma, Hepatocellular 76Sarcoma 75Esophageal Neoplasms 71Head and Neck Neoplasms 68Adenocarcinoma 67Triple Negative Breast Neoplasms 65Colonic Neoplasms 53Testicular Neoplasms 52Disease 47Wilms Tumor 46Urologic Neoplasms 45

Interventions

sipuleucel-T 2enzalutamide 2gallium 68 PSMA-11 1Vancomycin 1Metronidazole 1Docetaxel 1Ciprofloxacin 1Amoxicillin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Metastatic Castration-Resistant Prostate Cancer (mCRPC) × Genitourinary × 1 year × Clear all
NCT05806814 2026-05-27

OU-SCC-EXCITE

University of Oklahoma

Phase 1 Active not recruiting
15 enrolled
Genitourinary

Metastatic Castration-Resistant Prostate Cancer (mCRPC)

NCT05658003 2026-03-23

A Study Evaluating [177Lu]Lu-PSMA-617 vs. a Change of Androgen Receptor-directed Therapy in Taxane Treatment Naive Chinese Male Patients With Progressive Metastatic Castrate Resistant Prostate Cancer

Novartis

Phase 2 Active not recruiting
63 enrolled
Genitourinary

Metastatic Castration-Resistant Prostate Cancer (mCRPC)

NCT05670106 2026-02-13

A Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Dosimetry of [177Lu]Lu-PSMA-617 in Chinese Adult Male Patients With Progressive PSMA-Positive mCRPC

Novartis

Phase 2 Active not recruiting
62 enrolled
Genitourinary

Metastatic Castration-Resistant Prostate Cancer (mCRPC)

NCT06126731 2025-11-24

Combination Study of Antibiotics With Enzalutamide (PROMIZE)

Institute of Cancer Research, United Kingdom

Phase 1/2 Recruiting
39 enrolled
Genitourinary

Metastatic Castration-Resistant Prostate Cancer (mCRPC)

NCT06134232 2025-08-27

ProvONE

Dendreon

Phase 2 Recruiting
400 enrolled
Genitourinary

Metastatic Castration-Resistant Prostate Cancer (mCRPC)

NCT04015622 2025-08-20

PROTRACT

British Columbia Cancer Agency

Phase 2 Active not recruiting
100 enrolled
Genitourinary

Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Data powered by HemOnc (CC BY 4.0) Colophon âš¡